Post on 11-Jan-2016
description
Cytometry of Cell Signaling:Simultaneous Analysis of Multiple
Signaling Pathways in AML
T. Vincent Shankey, Ph.D.Systems Research/Life Sciences Division
Beckman Coulter, IncMiami, FL
Vincent.Shankey@Coulter.com
Control
P-ERK-Alexa 488
FA/Triton X-100
40 uM PMA
FA/TX/MeOH
Control
40 uM PMA
P-ERK-Alexa 488
Advantages of Whole Blood Sampling for Signal Transduction Pathway Analysis
• Sample Processing Speed– No cell separation step(s)– Rapid fixation minimizes potential for spontaneous de-
phosphorylation of target epitopes (cytoplasmic phosphatases)
– Ideal for use in clinical setting• Minimal Cell Loss
– Cell separation techniques can deplete specific cell types• Keeps Target Cell Populations in Contact with Pathway
Inhibitors (Targeted Therapeutics)– Rapid loss/reversal of in vivo pathway inhibition after
removal of cells from serum
Measurement of Cell Signaling
Bone Marrow
Acute Myeloid Leukemia (AML)(used with CD45, CD34, CD13/33, CD117)
David Hedley, Princess Margaret Hospital
(GDC-0941)
Hematopoietic Differentiation
Peripheral Circulation
CD34+CD117+/-
Gating/Analysis Protocol for Bone Marrow Signaling Analysis
+SCF
+GM-SCF
Rapid Activation/Inactivation of P-ERK in Normal Bone Marrow CD34+/CD117+ Cells
James Jacobberger, Case Western Reserve University
Signaling Responses in Normal CD34+/CD117+ cells
James Jacobberger, Case Western Reserve University
Signaling Responses in Normal CD34+/CD117+ cells
Signaling Response in AML Bone Marrows
01
23
4
5
0
1
2
0
20
40
60
Interpolated
James Jacobberger, Case Western Reserve University
SCF stimulated P-S6 and P-Erk
AML1 = M4AML2 = M2AML3 = M4eoAML4 = M5bAML5 = M1
0
20
40
60
0
1
2
3
4
5
6
7
8
0.0
0.51.0
1.52.0
AML1 AML3 AML5 NBM
pS6
(MF
I)
pERK (M
FI)
Time (min)
Flt3L-stimulated P-S6 and P-Erk
A B C
Side Scatter
Fig 1
100
101
102
103
104
100
101
102
103
104
0 16384 32768 49152 6553610
0
101
102
103
104
CD64
APC
CD117 PeCy5.5Side Scatter
CD34
ECD
CD13
Pe
Cy7
CD64
APC
CD16 Alexa 700Side Scatter
D E
Lymphs
Non Lymphs
Stem EnrichBlast
CD34+CD117+
CD34-CD117+
Monocytes
Myeloid Enrich Immature Myeloid
Intermediate Myeloid
Mature Myeloid
CD45
APC
Al
exa
750
Gating/Analysis Protocol for Bone Marrow Signaling Analysis
Chuck Goolsby, Northwestern University
Chuck Goolsby, Northwestern University
Growth Factor Receptor Expression Profiles for the Six Non-Lymphoid Cell Populations from Normal Bone Marrow
Normal Bone Marrow: P-ERK (S/N)
34+/117+ 34-/117+ Mono G1 G2 G302468
10121416
SCF
FLT3
IL3
GMCSF
GCSF
13.3
8.8
1.5 2.2 2.2 2.5
11.99.8
12.4
2.2 2.2 2.6
12.2
1
15.6
5.4 6.3 6.7
10.6
3.5
12.1
6.2
9.411.3
10.2
7.4
1
56.5 6.8
SCF FLT3 IL3 GMCSF
Chuck Goolsby, Northwestern Univ
34+/117+ 34-/117+ Mono G1 G2 G30
5
10
15
20
25
30
SCF
FLT3
IL3
GMCSF
GCSF
1 1 1 1 1 1
1 1 1 1 1 1
19.8
12.3 12.7 13.8 14.217.7
20.5
14.3 13.616.8 18.3
24.1
25.2
13.5
6.58.7 9.7
11.7
SCF FLT3 IL3 GMCSF
Normal Bone Marrow: P-STAT5 (S/N)
Chuck Goolsby, Northwestern Univ
34+/117+ 34-/117+ Mono G1 G2 G30
5
10
15
SCF
FLT3
IL3
GMCSF
GCSF
1 1 1 1 1 1
1 1 1 1 1 1
2.91 1 1 1 1
1 1 1
7.8 7.69.2
10.2 10.4
6.9
14 14.2 14.8
SCF FLT3 IL3 GMCSF
Chuck Goolsby, Northwestern Univ
Normal Bone Marrow: P-STAT3 (S/N)
Normal bone marrow cells show highly reproducible signaling pathways that
correlate with the differentiation state and the presence of specific cell surface
cytokine receptors
Chuck Goolsby, Northwestern University
AML – Categories of Abnormal Bone Marrow Signaling
Constitutive Activation
P-STAT5 P-Akt
Receptor Dysregulation
Abnormal Kinetics
GM-CSF
P-Akt
SCF
Aberrant Signaling Patterns in AML Bone Marrow Samples
Measurement of Cell Signaling
Whole Blood
Acute Myeloid Leukemia (AML)(used with CD45, CD34, CD13/33, CD117)
David Hedley, Princess Margaret Hospital
(GDC-0941)
David Hedley, Princess Margaret Hospital
David Hedley, Princess Margaret Hospital
David Hedley, Princess Margaret Hospital
David Hedley, Princess Margaret Hospital
David Hedley, Princess Margaret Hospital
David Hedley, Princess Margaret Hospital
Patient #106 FLT3/ITD
pSTAT5
Daily Oral Dose 225mg
FL2 INT LOG
SS
INT
LIN
100 101 102 103 104
0
256
512
768
1024
Control
FL2 INT LOG
SS
INT
LIN
100 101 102 103 104
0
256
512
768
1024
FL2 INT LOG
SS
INT
LIN
100 101 102 103 104
0
256
512
768
1024
FL2 INT LOG
SS
INT
LIN
100 101 102 103 104
0
256
512
768
1024
P-STAT5FL2 INT LOG
SS
INT
LIN
100 101 102 103 104
0
256
512
768
1024
ENMD20761.6uM
FL5 INT LOG
SS
INT
LIN
100 101 102 103 104
0
256
512
768
1024
Pre-dose
CD117+Blasts
Day 8
FL5 INT LOG
SS
INT
LIN
100 101 102 103 104
0
256
512
768
1024
FL5 INT LOG
SS
INT
LIN
100 101 102 103 104
0
256
512
768
1024
FL5 INT LOG
SS
INT
LIN
100 101 102 103 104
0
256
512
768
1024
Day 29 Day 211 15% 0.17% 0.03% 0.8%
CD117
David Hedley, Princess Margaret Hospital
Signaling Classification of AML(Work in Progress)
Real-time Monitoring of Molecular Targeted Therapeutics
Monitoring Bcr/Abl kinase inhibitor Imatinib in CML patients
Sequential flow data shows target inhibition in this patient, but incomplete as additional treatment with Imatinib ex vivo causes further decrease in p-STAT5.
Implication is that if we had this information, we would adjust the drug dose
D.W.Hedley, C. Goolsby, and T.V. Shankey. Tox Pathol 36;133-139, 2008
p-Stat5
Count
p-Stat5
Count
p-Stat5
Count
CD34+ cellsPre-therapy
Three weeksPost-therapy
Three weeks Post-therapy In vitro imatinibtreated
p-Stat5
Count
Count
p-Stat5
Count
p-Stat5
Count
p-Stat5
Count
p-Stat5
Count
CD34+ cellsPre-therapy
Three weeksPost-therapy
Three weeks Post-therapy In vitro imatinibtreated
Patient #2 –SCF activation David Hedley, Princess Margaret Hospital
AML Blast Response to Gleevec
Summary - AML Blast Response to in vivo Gleevec Treatment
P-Akt levels at D4/t2 predicts clinical response to subsequent Chemotherapy(p=0.008)
AML - Conclusions
• Normal bone marrow stem cells, monocytic and myeloid cells have distinct and restricted signaling “fingerprints”– AML blasts (bone marrow or peripheral blood) have
signaling patterns distinct from normal
• Signaling characteristics of peripheral blood and bone marrow stem-like cells appear similar (needs validation)
• Real-time monitoring of signaling pathways is useful in following response to therapies
Need for Automation!
Manual Assay Kinetics
Tube Contents LPS / 37º Add LPSAdd
Formaldehyde Add Triton
1 14 +p38 - no lps 0.00 31.20 46.20
2 14+p38 LPS Test 2 2.00 29.10 31.10 46.10
3 14+p38 LPS Test 3 4.00 27.00 31.00 46.00
4 14+p38 LPS Test 4 6.00 24.50 30.50 45.50
5 14+p38 LPS Test 5 8.00 22.40 30.40 45.40
6 14+p38 LPS Test 6 10.00 20.30 30.30 45.30
7 14+p38 LPS Test 7 15.00 15.20 30.20 45.20
8 14+p38 LPS Test 8 20.00 10.10 30.10 45.10
9 14+p38 LPS Test 9 30.00 0 min 30.00 45.00
Throughput requirements: • No info.
Blood sample in vacutainer
Aliquot up to100 uL per tube (up to 32 tubes/patient)
Add 5 uL of activator (LPS @ 37C or RT) and/or inhibitor to activation tubes or 5 uL of PBS to the control tube
Incubate at 37 C for 10-60 min
Add 65uL of 10% formaldehyde at RT
Vortex
Incubate for 10 min (exact) at RT
Add 1 mL of 0.1165% Triton X-100 in PBS at RT
Pippet up and downIncubate for 15 min at 37C
Add 2 mL of cold (4 C, possibly RT) PBS+4%FCSSpin at 1000xg, 3 min
Remove supernatant/resuspend pellet with residual buffer
Add 1 mL of “RT” 50-80% MeOH in PBS
Spin at 1000xg, 3 min
Add 2 mL of PBS+4%FCS (cold)
Remove supernatant
Spin at 1000xg, 3 minRemove supernatant as much as possible
Add Abs and cold (4C) PBS+4%FCS to a final volume of 100 uL
Incubate at RT for 30 min in dark
Add 2 mL of cold (4 C) wash buffer
Spin at 1000xg, 3 minRemove supernatant
Place the tubes (barcoded) on a 32 tube carouselAnalyze on a FC500 or CRS
Resuspend cells in 1 mL wash buffer
Cell Signaling Sample Preparation
Pipette up and down right after addition of MeOH, incubate at ? C for ? min
Up to 2 washes
June 30, 2009
Biomek NXp
AccessoriesDeck Layout
Centrifuge
Gallios
Assay Automation Tools
Shaking/Temperature Cycling Peltier
48 deep-wellplate
Adapter
Peltier
0
5
10
15
20
25
30
35
40
45
90.00 100.00 110.00 120.00 130.00 140.00 150.00 160.00 170.00 180.00
Elapse Time
Tem
p C
deg
Column 1
Column 2
Column 3
Column 4
Column 5
Column 6
Column 7
Column 8
Temperature Cycling in Wells
10 min
15 min
2 min 2 min 5 min 5 min 10 min 10 min 15 min 15 min 30 min 30 min0
2
4
6
8
10
12
14
16
Automation LPS Kinetics P-p38+P-ERK
P-p38 37 deg Contr
P-p38 LPS
Time Interval
MF
I
0
5
10
15
20
25
30
35
40
45
0.50 2.50 4.50 6.50 8.50 10.50 12.50 14.50 16.50 18.50 20.50 22.50 24.50 26.50 28.50 30.50 32.50 34.50 36.50 38.50
"°C"1
"°C"2
"°C"3
"°C"4
"°C"5
"°C"6
"°C"7
"°C"8
Temperature Cycling in WellsModified Shaking Peltier w fluid interface
2 min5 min
5 min fixation 4 min fixation 3 min fixation
2 min fixation 1 min fixation
Impact of fixation time at 37 deg C on light scatter profiles
0
5
10
15
20
25
30
35
40
45
0.50 2.50 4.50 6.50 8.50 10.50 12.50 14.50 16.50 18.50 20.50 22.50 24.50 26.50 28.50 30.50 32.50 34.50 36.50 38.50
"°C"1
"°C"2
"°C"3
"°C"4
"°C"5
"°C"6
"°C"7
"°C"8
Impact of fixation time at 37 deg C on P-p38 S/N
Signal to Noise for Fixation Kinetic study at 37°C Wet Coupling Biomek
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
1 2 3 4 5
Fixation Time (mins)
S/N S/N Biomek (p38)
Controls (p38)
S/N = 7.86
S/N = 6.50
SS
CD14 PC7 P-ERK
Automated Assay
Manual Assay
Comparison of Manual vs Automated Signaling Assays
pERK Signal after Biomek NXp 2 minutes LPS activation. Cells reconstitution in
Wash buffer or Formaldehyde
0
10
20
30
40
50
Well 1 Well 2 Well 3 Well 4
Well
MF
I
Wash Buffer 0.1% Form 0.5% Form
pS6 Signal after Biomek NXp 2 minutes LPS activation. Cells reconstitution in
Wash buffer or Formaldehyde
0
8
16
24
32
Well 1 Well 2 Well 3 Well 4
Well
MF
I
Wash Buffer 0.1% Form 0.5% Form
p38 Signal after Biomek NXp 2 minutes LPS activation. Cells reconstitution in
Wash buffer or Formaldehyde
0
8
16
24
32
Well 1 Well 2 Well 3 Well 4
Well
MF
I
Wash Buffer 0.1% Form 0.5% Form
%CV of Biomek NXp 2min LPS Activation Assay. Four Replicates of pERK, pS6 and
p38 Signals for cells reconstituted in Wash Buffer of Formaldehyde
0.00
4.00
8.00
12.00
16.00
WashBuffer
0.1% Form 0.5% Form
Reconstitution Medium
%C
VpERK
pS6
p38
pERK Signal after Biomek NXp 2 minutes LPS activation. Cells reconstitution in
Wash buffer or Formaldehyde
0
10
20
30
40
50
Well 1 Well 2 Well 3 Well 4
Well
MF
I
Wash Buffer 0.1% Form 0.5% Form
pS6 Signal after Biomek NXp 2 minutes LPS activation. Cells reconstitution in
Wash buffer or Formaldehyde
0
8
16
24
32
Well 1 Well 2 Well 3 Well 4
Well
MF
I
Wash Buffer 0.1% Form 0.5% Form
p38 Signal after Biomek NXp 2 minutes LPS activation. Cells reconstitution in
Wash buffer or Formaldehyde
0
8
16
24
32
Well 1 Well 2 Well 3 Well 4
Well
MF
I
Wash Buffer 0.1% Form 0.5% Form
%CV of Biomek NXp 2min LPS Activation Assay. Four Replicates of pERK, pS6 and
p38 Signals for cells reconstituted in Wash Buffer of Formaldehyde
0.00
4.00
8.00
12.00
16.00
WashBuffer
0.1% Form 0.5% Form
Reconstitution Medium
%C
VpERK
pS6
p38
CV’s of Current Automated Assay for P-ERK, P-p38 and P-S6
Biomek NXp 2
Biomek NXp1
S/N = 25.10 S/N = 14.70 S/N = 16.01
S/N = 17.80 S/N = 27.35 S/N = 14.50
P-ERK Alexa 647 P-S6 Pac BlueP-p38 Alexa 488
10 LPS Activation Comparison of 2 Biomeks
Collaborators
ACCG/Cytometry Consortium
David Hedley/Sue Chow /Qing Chang– Ontario Cancer Institute, UHN, Toronto, Ont.
Chuck Goolsby/James Marvin – Northwestern University, Chicago, ILJim Jacobberger/Phil Woost - Case Western Reserve Univ, Cleveland, OH
Beckman Coulter
Patty Grom, Lilly Lopez – Advanced Technology/Systems ResearchMeryl Forman & Co (Ltd) – Advanced TechnologyBob Zigon/Ernie Anderson – Kaluza Software Development
Systems Research Automation Group
Kelechi Eluwa
Valentin Quesada
Bob Auer
Lilly Lopez
Sergei Gulnik
T. Vincent Shankey